Stephanie J. Schrag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephanie J. Schrag has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Allen S. Craig
1 shared publicationAnn Thomas
1 shared publicationAnne Schuchat
Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Atlanta, Georgia
1 shared publicationArthur Reingold
California Emerging Infections Program, Berkeley, California
1 shared publication- Clare L. Cutland
Wits African Leadership in Vaccinology Expertise (Wits-Alive), School of Pathology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa
1 shared publication - David K. Shay
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Influenza Division, Atlanta, GA, USA
1 shared publication
Latest Publications
- 1 February 2016
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 127 (2) , 199-201
Maternal Immunization to Prevent Neonatal Group B Streptococcal Disease
- 1 February 2016
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 127 (2) , 199-201
Maternal Immunization to Prevent Neonatal Group B Streptococcal Disease
- 1 August 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (8) , 821-826
Risk Factors for Neonatal Sepsis and Perinatal Death Among Infants Enrolled in the Prevention of Perinatal Sepsis Trial, Soweto, South Africa
Background: Factors associated with neonatal sepsis, an important cause of child mortality, are poorly described in Africa. We characterized factors associated with early-onset (days 0–2 of life) and late-onset (days 3–28) sepsis and perinatal death among infants enrolled in the Prevention of Perinatal Sepsis Trial (NCT00136370 at ClinicalTrials.gov ), Soweto, South Africa. Methods: Secondary analysis of 8011 enrolled mothers and their neonates. Prenatal and labor records were abstracted and neonatal wards were monitored for hospitalized Prevention of Perinatal Sepsis–enrolled neonates. Endpoint definitions required clinical and laboratory signs. All univariate factors associated with endpoints at P < 0.15 were evaluated using multivariable logistic regression. Results: About 10.5% (837/8011) of women received intrapartum antibiotic prophylaxis; 3.8% of enrolled versus 15% of hospital births were preterm. Among 8129 infants, 289 had early-onset sepsis, 34 had late-onset sepsis, 49 had culture-confirmed neonatal sepsis and 71 died in the perinatal period. Factors associated with early-onset sepsis included preterm delivery [adjusted relative risk (aRR) = 2.6; 95% confidence interval (CI): 1.4–4.8]; low birth weight (<1500 g: aRR = 6.5, 95% CI: 2.4–17.3); meconium-stained amniotic fluid (MSAF) (aRR = 2.8, 95% CI: 2.2–3.7) and first birth (aRR = 1.8; 95% CI: 1.4–2.3). Preterm, low birth weight, MSAF and first birth were similarly associated with perinatal death and culture-confirmed sepsis. MSAF (aRR = 2.4, 95% CI: 1.1–5.0) was associated with late-onset sepsis. Conclusions: Preterm and low birth weight were important sepsis risk factors. MSAF and first birth were also associated with sepsis and death, warranting further exploration. Intrapartum antibiotic prophylaxis did not protect against all-cause sepsis or death, underscoring the need for alternate prevention strategies.
- 1 August 2012
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (8) , 821-826
Risk Factors for Neonatal Sepsis and Perinatal Death Among Infants Enrolled in the Prevention of Perinatal Sepsis Trial, Soweto, South Africa
Background: Factors associated with neonatal sepsis, an important cause of child mortality, are poorly described in Africa. We characterized factors associated with early-onset (days 0–2 of life) and late-onset (days 3–28) sepsis and perinatal death among infants enrolled in the Prevention of Perinatal Sepsis Trial (NCT00136370 at ClinicalTrials.gov ), Soweto, South Africa. Methods: Secondary analysis of 8011 enrolled mothers and their neonates. Prenatal and labor records were abstracted and neonatal wards were monitored for hospitalized Prevention of Perinatal Sepsis–enrolled neonates. Endpoint definitions required clinical and laboratory signs. All univariate factors associated with endpoints at P < 0.15 were evaluated using multivariable logistic regression. Results: About 10.5% (837/8011) of women received intrapartum antibiotic prophylaxis; 3.8% of enrolled versus 15% of hospital births were preterm. Among 8129 infants, 289 had early-onset sepsis, 34 had late-onset sepsis, 49 had culture-confirmed neonatal sepsis and 71 died in the perinatal period. Factors associated with early-onset sepsis included preterm delivery [adjusted relative risk (aRR) = 2.6; 95% confidence interval (CI): 1.4–4.8]; low birth weight (<1500 g: aRR = 6.5, 95% CI: 2.4–17.3); meconium-stained amniotic fluid (MSAF) (aRR = 2.8, 95% CI: 2.2–3.7) and first birth (aRR = 1.8; 95% CI: 1.4–2.3). Preterm, low birth weight, MSAF and first birth were similarly associated with perinatal death and culture-confirmed sepsis. MSAF (aRR = 2.4, 95% CI: 1.1–5.0) was associated with late-onset sepsis. Conclusions: Preterm and low birth weight were important sepsis risk factors. MSAF and first birth were also associated with sepsis and death, warranting further exploration. Intrapartum antibiotic prophylaxis did not protect against all-cause sepsis or death, underscoring the need for alternate prevention strategies.
- 1 July 2011
- Published by Elsevier in The Lancet
- Vol. 378 (9785) , 11-12
Group B streptococcal vaccine for resource-poor countries
- 1 July 2011
- Published by Elsevier in The Lancet
- Vol. 378 (9785) , 11-12
Group B streptococcal vaccine for resource-poor countries
- 1 August 2006
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 118 (2) , 570-576
Risk Factors for Invasive, Early-Onset Escherichia coli Infections in the Era of Widespread Intrapartum Antibiotic Use
OBJECTIVE. The goal was to evaluate risk factors for invasive Escherichia coli infections in the first week of life (early onset), focusing on the role of intrapartum antibiotic use.
- 1 August 2006
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 118 (2) , 570-576
Risk Factors for Invasive, Early-Onset Escherichia coli Infections in the Era of Widespread Intrapartum Antibiotic Use
OBJECTIVE. The goal was to evaluate risk factors for invasive Escherichia coli infections in the first week of life (early onset), focusing on the role of intrapartum antibiotic use.
- 1 May 2006
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 25 (5) , 395-400
Multistate Surveillance for Laboratory-Confirmed, Influenza-Associated Hospitalizations in Children
Increasing use of rapid influenza diagnostics facilitates laboratory confirmation of influenza infections. We describe laboratory-confirmed, influenza-associated hospitalizations in a population representing almost 6% of children in the United States. We conducted population-based surveillance for influenza-associated hospitalizations between October 1, 2003, and March 31, 2004, in 54 counties in 9 states (4.2 million children) participating in the Emerging Infections Program Network. Clinical characteristics, predictors of intensive care unit admission and geographic and age-specific incidence were evaluated. Surveillance identified 1,308 case-patients; 80% were or=6 months old had received at least one influenza vaccine dose that season. The overall incidence of influenza-associated hospitalizations was 36 per 100,000 children (range per state, 10 per 100,000 to 86 per 100,000). Influenza was an important cause of hospitalizations in children during 2003-2004. Hospitalizations were particularly common among children <6 months of age, a group for whom influenza vaccine is not licensed. Continued surveillance for laboratory-confirmed influenza could inform prevention strategies.
- 1 May 2006
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 25 (5) , 395-400
Multistate Surveillance for Laboratory-Confirmed, Influenza-Associated Hospitalizations in Children
Increasing use of rapid influenza diagnostics facilitates laboratory confirmation of influenza infections. We describe laboratory-confirmed, influenza-associated hospitalizations in a population representing almost 6% of children in the United States. We conducted population-based surveillance for influenza-associated hospitalizations between October 1, 2003, and March 31, 2004, in 54 counties in 9 states (4.2 million children) participating in the Emerging Infections Program Network. Clinical characteristics, predictors of intensive care unit admission and geographic and age-specific incidence were evaluated. Surveillance identified 1,308 case-patients; 80% were or=6 months old had received at least one influenza vaccine dose that season. The overall incidence of influenza-associated hospitalizations was 36 per 100,000 children (range per state, 10 per 100,000 to 86 per 100,000). Influenza was an important cause of hospitalizations in children during 2003-2004. Hospitalizations were particularly common among children <6 months of age, a group for whom influenza vaccine is not licensed. Continued surveillance for laboratory-confirmed influenza could inform prevention strategies.